跳至主要内容
临床试验/CTRI/2025/02/081287
CTRI/2025/02/081287尚未招募不适用

Evaluation of the Efficacy and In Use Safety of Skin Care Formulation in Female Subjects with Postinflammatory Hyperpigmentation

Sun Pharmaceutical Industries Ltd.1 个研究点 分布在 1 个国家目标入组 115 人开始时间: 2025年1月3日

试验速览

阶段
不适用
状态
尚未招募
入组人数
115
试验地点
1
主要终点
Reduction in pigmentary intensity

研究概览

简要总结

OBJECTIVE

Primary Objective:

To assess the efficacy of skin care formulation, skinlightening face serum in female subjects with visible facial PIH.

Secondary Objective:

To assess the safety and cosmetic appeal of skin careformulation, skin lightening face serum in female subjects with visible facialPIH.

STUDY DESIGN

This is a non-comparative, prospective, interventionalstudy.

STUDY POPULATION

Enrollment: 128 subjects with facial PIH.

Completed: 115.

The subjects selected for this study are femalesubjects of 18-40 years of age having Fitzpatrick skin type III-V and havingvisible facial PIH (at least one spot of 3mm size).

STUDY DURATION

Screening period: 1 day

Treatment period: 84 days (i.e., 12 weeks)

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • Indian female subjects 2)Having Fitzpatrick Skin type 3 to 5 3)Having facial PIH with at least one dark spot more than or equal to 3mm in diameter.
  • Willing to sign the informed consent form to participate in the study and to comply to the protocol and study procedures.

排除标准

  • Female who is pregnant or breastfeeding or has stopped breastfeeding in the past three months 2)Participating in another study liable to interfere with this study 3)Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 4)Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 5)Having progressive asthma 6)Being epileptic 7)Having non stabilized thyroid problems 8_Having cutaneous hypersensitivity 9)Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex 10)Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) for more than 1 year.
  • Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.
  • Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
  • Having applied a cosmetic product (included make-up) on the studied areas the first day of the study (only face cleaned with water is accepted).
  • Having started, changed or stopped a hormonal treatment (hormonal contraception, Hormone Replacement Therapy) in the past 3 months.

结局指标

主要结局

Reduction in pigmentary intensity

时间窗: Baseline, Day 14, Day 28, Day 56 and Day 84

次要结局

  • Safety and cosmetic appeal(Baseline, Day 14, Day 28, Day 56 and Day 84)

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验